The Valley Desk

NCT01714739 · Interventional trial

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Overall registry status Completed

Phase 1 · Phase 2

Conditions CANCER,NOS

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov